FEG
IBRX icon

Financial Enhancement Group’s ImmunityBio IBRX Stock Holding History

Financial Enhancement Group’s Portfolio IBRX Stock Details IBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$87.5K Hold
10,000
– – 0.01% 137
2026
Q1 		$77K Hold
10,000
– – 0.01% 135
2025
Q4 		$69.2K Hold
10,000
– – 0.01% 135
2025
Q3 		$25.3K Hold
10,000
– – ﹤0.01% 132
2025
Q2 		$28.1K Buy
+10,000
New +$26.9K ﹤0.01% 128

Other funds holding IBRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Financial Enhancement Group's IBRX Position: Q2 2026 in Review

Financial Enhancement Group held its ImmunityBio (IBRX) position steady in Q2 2026 at 10,000 shares worth $87.5K. The position accounts for 0.01% of the portfolio, ranked #137.

Financial Enhancement Group first reported a position in IBRX in Q2 2025 and has held it in 5 quarters since. 404 funds tracked by Wall St. Rank hold IBRX as of Q2 2026.

  • Financial Enhancement Group held 10,000 shares of ImmunityBio worth $87.5K as of Q2 2026.
  • Financial Enhancement Group left its ImmunityBio share count unchanged in Q2 2026.
  • ImmunityBio made up 0.01% of Financial Enhancement Group's portfolio in Q2 2026, its #137 holding.
  • Financial Enhancement Group first reported a position in ImmunityBio in Q2 2025 and has held it in 5 quarters since.
  • 404 funds tracked by Wall St. Rank held ImmunityBio as of Q2 2026.

Based on Financial Enhancement Group's 13F filing for Q2 2026, filed 7 Jul 2026.